Company: BLLN
Filing Date: 2025-09-17
Form Type: DRS/A
Source: 0001193125-25-206347
Chunk: 368

Company: BillionToOne, Inc.
Filing Date: 2025-09-17
Form: DRS/A
Chunk 368
---
 intrinsic value is calculated as the difference between the exercise price of the underlying stock option award and the estimated fair value of the Company’s common stock. The total intrinsic values of options exercised during the years ended December 31, 2023 and 2024 was $1.2 million and $4.7 million, respectively. During the year ended December 31, 2023, the weighted average grant-date fair value of options granted was $7.75 per share, and the fair value of options vested during the period was $4.4 million. During the year ended December 31, 2024, the weighted average grant-date fair value of options granted was $10.89 per share, and the fair value of options vested during the period was $7.2 million. The fair value is being expensed over the vesting period of the options, on a straight-line basis as the services are being provided. As of December 31, 2024 there was approximately $22.2 million of total unrecognized compensation cost related to unvested options, which is expected to be recognized over the weighted average period of 2.6 years. F-32

B ILLIONT OO NE, INC. Notes to Financial Statements Restricted Stock Award Activity A summary of the Company’s restricted stock award activity and related information is as follows:

|                                   |     | Awards |         |   |     | Weighted-       
 Average Grant   
 Date Fair Value 
 (per share)     |      |
|:----------------------------------|:----|:-------|--------:|:--|:----|:----------------|-----:|
| Nonvested as of January 1, 2023   |     |        |  14,584 |   |     | $               | 0.35 |
| Issued                            |     |        |       - |   |     |                 |    - |
| Vested                            |     |        | (14,584 | ) |     |                 | 0.35 |
| Forfeited                         |     |        |       - |   |     |                 |    - |
| Nonvested as of December 31, 2023 |     |        |       - |   |     |                 |    - |

There was no restricted stock award activity during the year ended December 31, 2024. Stock-Based Compensation Expense The table below shows stock-based compensation expense included in the statements of operations and comprehensive loss for the years ended December